IXICO PLC

IXI
Delayed Quote. Delayed  - 01/25 11:35:24 am
80.8GBX -6.59%

IXICO : to Present at Innovation Forum

02/10/2020 | 04:18am
RNS Reach Story
Go to market news section
IXICO plc - IXI
IXICO to Present at Innovation Forum
Released 09:11 10-Feb-2020



RNS Number : 4717C
IXICO plc
10 February 2020

10 February 2020

IXICO plc

('IXICO' or the 'Company')

IXICO to Present at the Annual Shares Magazine/Cenkos Growth and Innovation Forum

on 11th February 2020

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that the Company will be attending and presenting at the Shares Magazine/Cenkos Growth and Innovation Forum on Tuesday, 11 February 2020 at the London Business Design Centre.

Giulio Cerroni, IXICO's Chief Executive Officer, will be attending the event and presenting at 12:15pm GMT in the Flowers Room.

Shares Magazine/Cenkos Growth and Innovation Forum:

Presentation: 12:15 PM GMT, 11 February 2020, Flowers Room

Exhibition: 09:00 AM - 5:00 PM GMT, 11 February 2020, Booth 25

London - Business Design Centre, London N1 52 Upper Street, Islington

The Shares Magazine/Cenkos Growth and Innovation Forum is one of the UK's major growth and technology focussed investment shows connecting investment experts, fund managers, company executives from fast-growing and technology-led London-listed companies.

For further information please contact:

IXICO plc

+44 (0) 20 3763 7498

Alison Howie, Chief Product Officer

Optimum Strategic Communications

+44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus

IXICO@optimumcomms.com

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAVBLBFBLLEBBV
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
©2014London Stock Exchange plc. All rights reserved



IXICO to Present at Innovation Forum - RNS

Disclaimer

IXICO plc published this content on 10 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 February 2020 09:17:03 UTC

© Publicnow 2021
Copier lien
All news about IXICO PLC
12/24
12/08
12/02
12/02
11/27